Avacta Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Author's Avatar
Dec 15, 2021

Avacta Group plc (AIM: AVCT), a clinical stage biopharmaceutical company developing innovative cancer therapies and powerful diagnostics based on its proprietary Affimer® and pre|CISION™ platforms is pleased to announce that the AffiDX® antigen lateral flow test has been shown to detect the Omicron variant of the SARS-CoV-2 virus in clinical samples.